Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 494 entries
View as:

One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

Phase: N/A Priority: Normal
NCT ID: NCT03662919 Org: User:
Start: 07/02/18 End: 06/30/22 Due: 06/30/23

Pregnancy Exposure Registry for Avonex (Interferon Beta-1a)

Phase: N/A Priority: Normal
NCT ID: NCT00168714 Org: User:
Start: 02/29/04 End: 09/30/11 Due: 09/30/12

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants

Phase: N/A Priority: Normal
NCT ID: NCT01706107 Org: User:
Start: 11/07/12 End: 10/02/15 Due: 10/02/16

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well

Phase: N/A Priority: Normal
NCT ID: NCT05764122 Org: User:
Start: 03/29/24 End: 07/07/25 Due: 07/07/26

A Study to Find Out How Multiple Doses of BIIB091 Affect the Electrical Activity of the Heart in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT06574828 Org: User:
Start: 08/29/24 End: 03/22/25 Due: 03/22/26

802NP301 Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia

Phase: N/A Priority: Normal
NCT ID: NCT03070132 Org: User:
Start: 04/19/23 End: 08/21/26 Due: 08/21/27

Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03454126 Org: User:
Start: 03/29/18 End: 04/30/19 Due: 04/30/20

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Phase: N/A Priority: Normal
NCT ID: NCT01211639 Org: User:
Start: 10/31/10 End: 08/31/14 Due: 08/31/15

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Phase: N/A Priority: Normal
NCT ID: NCT00818038 Org: User:
Start: 03/31/09 End: 03/31/11 Due: 03/31/12

A Study to Find Out How BIIB141 (Omaveloxolone) Moves From the Blood Into the Breastmilk of Healthy Women Who Are Breastfeeding or Pumping Milk

Phase: N/A Priority: Normal
NCT ID: NCT06612879 Org: User:
Start: 10/18/24 End: 04/08/25 Due: 04/08/26

BIIB033 In Acute Optic Neuritis (AON)

Phase: N/A Priority: Normal
NCT ID: NCT01721161 Org: User:
Start: 12/31/12 End: 10/31/14 Due: 10/31/15

Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Phase: N/A Priority: Normal
NCT ID: NCT00801060 Org: User:
Start: 02/29/08 End: 09/30/10 Due: 09/30/11

Immunogenicity and Safety Study of Serum-Free Avonex

Phase: N/A Priority: Normal
NCT ID: NCT00912860 Org: User:
Start: 01/31/03 End: 01/31/05 Due: 01/31/06

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01416155 Org: User:
Start: 10/31/10 End: 12/31/14 Due: 12/31/15

Pediatric Spinal Muscular Atrophy (SMA) China Registry

Phase: N/A Priority: Normal
NCT ID: NCT05042921 Org: User:
Start: 11/18/21 End: 09/02/27 Due: 09/02/28

Efficacy and Safety Study of BIIB074 in Participants With Small Fiber Neuropathy

Phase: N/A Priority: Normal
NCT ID: NCT03339336 Org: User:
Start: 05/31/18 End: 04/12/21 Due: 04/12/22

COMPliance With Avonex® PS in Patients With Relapsing-Remitting MS

Phase: N/A Priority: Normal
NCT ID: NCT00675883 Org: User:
Start: 05/31/08 End: 12/31/11 Due: 12/31/12

A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia

Phase: N/A Priority: Normal
NCT ID: NCT02917187 Org: User:
Start: 09/09/16 End: 01/05/17 Due: 01/05/18

Plegridy Satisfaction Study in Participants

Phase: N/A Priority: Normal
NCT ID: NCT02587065 Org: User:
Start: 02/03/16 End: 12/21/17 Due: 12/21/18

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT01064401 Org: User:
Start: 05/31/10 End: 07/31/14 Due: 07/31/15

A Study Of The Effects Of PF-04958242 In Subjects With Age-Related Hearing Loss

Phase: N/A Priority: Normal
NCT ID: NCT01518920 Org: User:
Start: 12/31/11 End: 02/28/13 Due: 02/28/14

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03716570 Org: User:
Start: 03/12/19 End: 04/23/21 Due: 04/23/22

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Phase: N/A Priority: Normal
NCT ID: NCT03093324 Org: User:
Start: 03/15/17 End: 06/27/19 Due: 06/27/20

Tecfidera Lymphocyte Chart Review

Phase: N/A Priority: Normal
NCT ID: NCT02519413 Org: User:
Start: 07/31/15 End: 02/29/16 Due: 02/28/17

Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Phase: N/A Priority: Normal
NCT ID: NCT03870763 Org: User:
Start: 03/19/19 End: 07/21/22 Due: 07/21/23